|[July 04, 2014]
Research and Markets: PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/qfvnhr/pharmapoint)
has announced the addition of the "PharmaPoint:
Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to
2022 - Event-Driven Update" report to their offering.
Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and
the second-most common cancer in men and women. Historically, the
treatment paradigm has centered around chemotherapy. However, the launch
of targeted therapies for patients with specific biomarkers has begun to
fragment the NSCLC treatment landscape into smaller niche patient
populations. Over the forecast period, this trend will continue with the
launch of multiple new drugs in several new drug classes to address the
high unmet need among NSCLCpatients, and provide new treatment options
for previously underserved populations.
Overview of NSCLC, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines.
Annualized NSCLC therapeutics market revenue, annual cost of therapy
and treatment usage pattern data by patient segment forecast from 2012
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and implications
for the NSCLC therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and
mechanisms of action under development for different lines of therapy.
The most promising 13 candidates in Phase III development are profiled.
Analysis of the current and future market competition in the global
NSCLC market. Insightful review of the key industry drivers,
restraints and challenges. Each trend is independently researched to
provide qualitative analysis of its implications.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Opportunity and Unmet Need
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
For more information visit http://www.researchandmarkets.com/research/qfvnhr/pharmapoint
[ Back To TMCnet.com's Homepage ]